VBI Vaccines Inc. Stock price Toronto S.E.

Equities

VBV

CA91822J1030

Biotechnology & Medical Research

Delayed Toronto S.E. 05:39:59 2018-03-23 pm EDT 5-day change 1st Jan Change
4.82 CAD -5.12% Intraday chart for VBI Vaccines Inc. -7.66% -10.58%
Sales 2023 * 13M 17.61M Sales 2024 * 20M 27.09M Capitalization 14.27M 19.33M
Net income 2023 * -98M -133M Net income 2024 * -21M -28.44M EV / Sales 2023 * 1.1 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 0.71 x
P/E ratio 2023 *
-0.09 x
P/E ratio 2024 *
-0.73 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 84.98%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 62 16-04-30
Director of Finance/CFO 36 15-07-08
Chief Tech/Sci/R&D Officer 54 16-05-05
Members of the board TitleAgeSince
Director/Board Member 63 23-04-23
Chairman 70 04-12-31
Chief Executive Officer 62 16-04-30
More insiders
VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6026 USD
Average target price
6 USD
Spread / Average Target
+895.69%
Consensus
  1. Stock
  2. Equities
  3. Stock VBI Vaccines Inc.
  4. Stock VBI Vaccines Inc. - Toronto S.E.